Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 162

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents

Goodarzi, Mark O., Bryer‐Ash, Michael · 2005 · Diabetes, Obesity and Metabolism

Abstract

Background: The usefulness of metformin as an oral antidiabetic agent is widely accepted. However, several other classes of oral antidiabetic agents have been recently introduced, raising the need to evaluate the role of metformin as initial therapy and in combination with these newer drugs for treatment of type 2 diabetes mellitus (DM). Methods: Synthesis of information was preceded by a comprehensive review of the English language literature using Medline. We also reviewed bibliographies of relevant articles. The studies most pertinent to the mechanism of action, efficacy, toxicity and administration of metformin were selected for citation in this review. Results: Metformin acts by increasing tissue sensitivity to insulin, principally in the liver. Beneficial properties of metformin include weight reduction, favourable effects on the lipid profile and the fibrinolytic pathway, and improvement of ovarian function in some insulin‐resistant women. It does not cause hyperinsulinaemia or hypoglycaemia. Metformin is effective as monotherapy and, in combination with both insulin secretagogues and thiazolidinediones (TZDs), may obviate the need for insulin treatment. Several fixed‐dose combination pills containing metformin and other agents are available. A protocol for the initiation of therapy with contemporary oral agents for type 2 DM is presented, with emphasis on the continuing central role of metformin. Conclusions: Metformin remains a safe and effective agent for the therapy of patients with type 2 DM. It is useful as monotherapy or in combination regimens with the newer insulin secretagogues, TZDs or insulin. It is still in most circumstances the agent of choice for initial therapy of the typical obese patient with type 2 DM and mild to moderate hyperglycaemia.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1463-1326.2004.00448.x

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Research works printed but not linked: 106

  1. Medvei VC, 1993, The History of Clinical Endocrinology, 365
  2. 10.1016/S0021-9258(18)86579-6 · DOI · Paper page
  3. 10.2337/diacare.12.8.553 · DOI · Paper page
  4. 10.1007/BF01263444 · DOI · Paper page
  5. 10.7326/0003-4819-87-5-591 · DOI
  6. 10.7326/0003-4819-83-4-567 · DOI
  7. Lucis OJ, 1983, The status of metformin in Canada, Can Med Assoc J, 128, 24
  8. Clarke BF, 1979, Biguanide treatment in the management of non‐insulin‐independent (maturity‐onset) diabetes: clinical experience with metformin, Res Clin Forums, 1, 53
  9. 10.1111/j.1464-5491.1987.tb00895.x · DOI
  10. 10.1007/BF00285334 · DOI
  11. 10.1136/bmj.4.5622.25 · DOI
  12. 10.2337/diabetes.32.12.1083 · doi:10.2337/diabetes.32.12.1083
  13. 10.2337/diab.36.5.632 · DOI · Paper page
  14. Ferner RE, 1988, Impaired beta‐cell responses improve when fasting blood glucose concentration is reduced in non‐insulin‐dependent diabetes, Q J Med, 66, 137
  15. 10.1146/annurev.pa.15.040175.002031 · DOI
  16. Hermann LS, 1979, Metformin: a review of its pharmacological properties and therapeutic use, Diabetes Metab, 5, 233
  17. Sterne J, 1984, Metformin: pharmacological mechanisms of the antidiabetic and antilipidic effects and clinical consequences, R Soc Med (Int Congr Symp Ser), 48, 3
  18. 10.2337/diab.17.8.492 · DOI
  19. 10.1056/NEJM197703032960906 · DOI
  20. 10.1210/jc.74.5.1020 · doi:10.1210/jc.74.5.1020
  21. 10.1530/acta.0.1200257 · DOI
  22. 10.2337/diacare.13.6.696 · DOI · Paper page
  23. 10.1111/j.1445-5994.1991.tb01375.x · DOI
  24. Fendri S, 1993, Metformin effects on peripheral sensitivity to insulin in non diabetic obese subjects, Diabetes Metab, 19, 245
  25. 10.2337/diab.43.7.920 · DOI · Paper page
  26. Galuska D, 1991, Metformin increases insulin‐stimulated glucose transport in insulin‐resistant human skeletal muscle, Diabetes Metab, 17, 159
  27. 10.1210/en.130.5.2535 · doi:10.1210/en.130.5.2535
  28. 10.1016/S0889-8529(18)30221-4 · DOI
  29. 10.2337/diacare.17.10.1100 · DOI · Paper page
  30. 10.1007/BF00403956 · DOI
  31. 10.1210/en.137.7.2990 · doi:10.1210/en.137.7.2990
  32. Valensi P, 2002, In vivo kinetics of 123 iodine‐labelled insulin in skeletal muscle of patients with type 2 diabetes. Effect of metformin, Diabetes Metab, 28, 95
  33. 10.1016/0026-0495(90)90259-F · DOI
  34. 10.2337/diabetes.42.8.1159 · DOI
  35. 10.2165/00003495-199958001-00009 · DOI · Paper page
  36. 10.1210/jc.2002-021394 · DOI · Paper page
  37. 10.2337/diabetes.48.6.1251 · DOI
  38. 10.1111/j.1432-1033.1993.tb17886.x · DOI
  39. 10.2337/diab.46.9.1406 · DOI
  40. 10.1016/S0005-2736(01)00352-2 · DOI
  41. 10.1016/S0006-2952(02)00858-4 · DOI
  42. 10.1074/jbc.M202489200 · DOI · Paper page
  43. 10.2337/diabetes.51.7.2074 · DOI · Paper page
  44. 10.2337/diabetes.49.6.896 · DOI · Paper page
  45. 10.2337/diab.37.12.1595 · DOI · Paper page
  46. 10.2337/diacare.16.7.1035 · DOI
  47. 10.1136/bmj.2.6102.1576 · DOI
  48. 10.2337/diabetes.51.12.3479 · DOI · Paper page
  49. 10.1210/jc.2002-021786 · DOI · Paper page
  50. Vigneri R, 1991, Treatment of NIDDM patients with secondary failure to glyburide: comparison of the addition of either metformin or bed‐time NPH insulin to glyburide, Diabetes Metab, 17, 232
  51. 10.1185/03007998209110114 · doi:10.1185/03007998209110114
  52. 10.1177/014107688908200213 · DOI
  53. Haupt E, 1991, Oral antidiabetic combination therapy with sulphonylureas and metformin, Diabetes Metab, 17, 224
  54. 10.1001/jama.283.13.1695 · DOI · Paper page
  55. 10.1111/j.1464-5491.1988.tb01074.x · DOI
  56. 10.1007/BF02581246 · DOI
  57. Klein W, 1991, Sulfonylurea‐metformin combination versus sulfonylurea‐insulin combination in secondary failures to sulfonylurea monotherapy, Diabetes Metab, 17, 235
  58. 10.2337/diacare.25.3.542 · DOI · Paper page
  59. 10.1007/BF00315466 · DOI · Paper page
  60. 10.2337/diacare.16.4.621 · DOI · Paper page
  61. 10.1016/S0140-6736(65)92383-4 · DOI
  62. Gin H, 1988, Effect of metformin on platelet hyperaggregation in the insulin‐dependent diabetic, Diabetes Metab, 14, 596
  63. 10.1136/bmj.310.6972.83 · DOI · Paper page
  64. 10.1385/ENDO:20:3:215 · DOI
  65. 10.1016/S0140-6736(98)07037-8 · DOI · Paper page
  66. 10.2337/diacare.25.12.2244 · DOI · Paper page
  67. 10.1007/BF01221950 · DOI · Paper page
  68. Coetzee EJ, 1980, Pregnancy in established non‐insulin‐dependent diabetics. A five‐and‐a‐half year study at Groote Schuur Hospital, S Afr Med J, 58, 795
  69. Coetzee EJ, 1984, Oral hypoglycaemics in the first trimester and fetal outcome, S Afr Med J, 65, 635
  70. 10.1002/tera.1420490405 · DOI
  71. 10.1046/j.1464-5491.2000.00314.x · DOI · Paper page
  72. 10.1093/ajcn/71.5.1242s · DOI · Paper page
  73. 10.1056/NEJM199806253382603 · DOI · Paper page
  74. 10.1007/s004040100176 · DOI
  75. 10.1016/S0015-0282(01)03202-2 · DOI · Paper page
  76. 10.1016/S0015-0282(00)01666-6 · DOI · Paper page
  77. 10.1210/jcem.87.2.8207 · DOI · Paper page
  78. 10.1016/S0015-0282(03)00734-9 · DOI
  79. 10.2165/00003495-199549050-00007 · DOI · Paper page
  80. 10.2165/00002018-199411040-00002 · DOI · Paper page
  81. Campbell I, 1985, Metformin and the sulfonylureas: the comparative risk, Horm Metab Res Suppl, 15, 105
  82. 10.2337/diacare.15.6.755 · DOI · Paper page
  83. 10.1016/S0140-6736(65)91893-3 · DOI
  84. 10.1136/bmj.2.6135.464 · DOI
  85. Hermann L, 1984, Metabolic effects of metformin in relation to clinical effects and side‐effects, R Soc Med (Int Congr Symp Ser), 48, 3
  86. 10.1136/bmj.280.6225.1214 · DOI · Paper page
  87. Scheen AJ, 1994, Reduction of the acute bioavailability of metformin by the alpha‐glucosidase inhibitor acarbose in normal man, Eur J Clin Invest, 24, 50, 10.1111/j.1365-2362.1994.tb02257.x · DOI · Paper page
  88. 10.1111/j.1365-2125.1987.tb03090.x · DOI · Paper page
  89. 10.2337/diacare.26.7.2069 · DOI
  90. 10.1002/cpt1978246683 · DOI · Paper page
  91. Lalau JD, 1990, Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly), Int J Clin Pharmacol Ther Toxicol, 28, 329
  92. 10.1016/S0002-9343(97)00254-4 · DOI · Paper page
  93. 10.2337/diacare.15.4.539 · DOI
  94. Groop L, 1991, Treatment strategies for secondary sulfonylurea failure. Should we start insulin or add metformin? Is there a place for intermittent insulin therapy?, Diabetes Metab, 17, 218
  95. 10.1007/BF02581286 · DOI
  96. 10.2337/diacare.22.1.119 · DOI · Paper page
  97. 10.2337/diacare.26.7.2063 · DOI
  98. 10.1016/S0149-2918(00)83039-8 · DOI · Paper page
  99. 10.1046/j.1463-1326.2003.00258.x · DOI
  100. 10.1002/dmrr.264 · DOI
  101. 10.1016/S0002-9343(00)00338-7 · DOI
  102. Leblanc H, 1987, Value of combined subcutaneous infusion of insulin and metformin in 10 insulin‐dependent obese diabetics, Diabetes Metab, 13, 613
  103. 10.1016/0002-9343(91)90041-U · DOI
  104. Yang J, 2003, Efffect of addition of low‐dose rosiglitazone to sulphonylurea therapy on glycemic control in type 2 diabetic patients, Chin Med J (Engl), 116, 785
  105. 10.1111/j.1464-5491.2004.01083.x · DOI
  106. 10.2337/diacare.25.10.1691 · DOI

Cited by

See all 162

Metadata

Authors
Goodarzi, M. O., & Bryer‐Ash, M.
Venue
Diabetes, Obesity and Metabolism
Publisher
Wiley
Published
2004-12-13
Volume
7
Issue
6
Pages
654-665
ISSN
  • 1462-8902 (ISSN-L)
  • 1463-1326
OpenAlex
W2039006908
Cited by
162
References
17
FWCI
1.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. https://app.cochat.ai/papers/10.1111/j.1463-1326.2004.00448.x
The paper
Goodarzi, M. O., & Bryer‐Ash, M. (2005). Metformin revisited: re‐evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2004.00448.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.